Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610611 | 0.92 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6478964 | 0.88 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6480235 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6480243 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6491088 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7148256 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6488870 | 0.82 | MAPK14 (0.81) | MAPK14 | |
| SCHEMBL6610606 | 0.81 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6478725 | 0.80 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6480614 | 0.79 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | claimed |
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY | 2004-06-24 | — | — | US | claimed |
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122025-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | MAPK14 1280/4885MAPK13 2833/4885MAPK12 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.